• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, April 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Artificial intelligence system created at UNC-Chapel Hill designs drugs from scratch

Bioengineer by Bioengineer
July 31, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.

The system is called Reinforcement Learning for Structural Evolution, known as ReLeaSE, and is an algorithm and computer program that comprises two neural networks which can be thought of as a teacher and a student. The teacher knows the syntax and linguistic rules behind the vocabulary of chemical structures for about 1.7 million known biologically active molecules. By working with the teacher, the student learns over time and becomes better at proposing molecules that are likely to be useful as new medicines.

Alexander Tropsha, Olexandr Isayev and Mariya Popova, all of the UNC Eshelman School of Pharmacy, are the creators of ReLeaSE. The University has applied for a patent for the technology, and the team published a proof-of-concept study in the journal Science Advances last week (DOI: 10.1126/sciadv.aap7885).

"If we compare this process to learning a language, then after the student learns the molecular alphabet and the rules of the language, they can create new 'words,' or molecules," said Tropsha. "If the new molecule is realistic and has the desired effect, the teacher approves. If not, the teacher disapproves, forcing the student to avoid bad molecules and create good ones."

ReLeaSE is a powerful innovation to virtual screening, the computational method widely used by the pharmaceutical industry to identify viable drug candidates. Virtual screening allows scientists to evaluate existing large chemical libraries, but the method only works for known chemicals. ReLeASE has the unique ability to create and evaluate new molecules.

"A scientist using virtual screening is like a customer ordering in a restaurant. What can be ordered is usually limited by the menu," said Isayev. "We want to give scientists a grocery store and a personal chef who can create any dish they want."

The team has used ReLeaSE to generate molecules with properties that they specified, such as desired bioactivity and safety profiles. The team used the ReLeaSE method to design molecules with customized physical properties, such as melting point and solubility in water, and to design new compounds with inhibitory activity against an enzyme that is associated with leukemia.

"The ability of the algorithm to design new, and therefore immediately patentable, chemical entities with specific biological activities and optimal safety profiles should be highly attractive to an industry that is constantly searching for new approaches to shorten the time it takes to bring a new drug candidate to clinical trials," said Tropsha.

###

About the University of North Carolina at Chapel Hill

The University of North Carolina at Chapel Hill, the nation's first public university, is a global higher education leader known for innovative teaching, research and public service. A member of the prestigious Association of American Universities, Carolina regularly ranks as the best value for academic quality in U.S. public higher education. Now in its third century, the University offers 77 bachelor's, 111 master's, 65 doctorate and seven professional degree programs through 14 schools and the College of Arts and Sciences. Every day, faculty, staff and students shape their teaching, research and public service to meet North Carolina's most pressing needs in every region and all 100 counties. Carolina's nearly 330,000 alumni live in all 50 states, the District of Columbia and 149 countries. More than 169,00 live in North Carolina.

Media Contact

Audrey Smith
[email protected]
919-445-8555
@unc

Home

http://dx.doi.org/10.1126/sciadv.aap7885

Share15Tweet8Share2ShareShareShare2

Related Posts

PHIP Inhibits NuRD to Boost SWI/SNF Cancer Growth

April 7, 2026

Enhancing Prime Editing with Engineered Non-Canonical pegRNAs

April 7, 2026

Sleep Quality Factors in Older Adults Revealed

April 7, 2026

Osteoarthritis and Painkiller Use in HFE C282Y Patients

April 7, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    97 shares
    Share 39 Tweet 24
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1009 shares
    Share 399 Tweet 249
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    44 shares
    Share 18 Tweet 11

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tsu-Jae Liu’s Editorial Explores the Impact of AI on Engineering Innovation

PHIP Inhibits NuRD to Boost SWI/SNF Cancer Growth

Targeted Therapy Boosts Immune Attack in Ovarian Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.